LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Home・Aandelen Lijst・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

43.99 1.31

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

43.8

Max

44.44

Belangrijke statistieken
By Trading Economics
Inkomsten	-6.2M -91M
Winstmarge	-867.293
Werknemers	316
EBITDA	4M -90M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+24.74% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	211M 3.4B
Vorige openingsprijs	42.68
Vorige sluitingsprijs	43.99

Nieuwssentiment

By Acuity

50%

158 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

34.81 / 38.24 Steun & Weerstand

Xenon Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 dec 2025, 22:53 UTC

Acquisities, Fusies, Overnames

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

13 dec 2025, 00:04 UTC

Acquisities, Fusies, Overnames

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

14 dec 2025, 23:46 UTC

Marktinformatie

Gold Edges Higher Amid Some Tailwinds -- Market Talk

14 dec 2025, 23:36 UTC

Marktinformatie

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

14 dec 2025, 22:38 UTC

Acquisities, Fusies, Overnames

Fortescue to Take Full Control of US$101M Copper Miner Alta

14 dec 2025, 22:02 UTC

Acquisities, Fusies, Overnames

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

14 dec 2025, 22:01 UTC

Acquisities, Fusies, Overnames

Fortescue: Alta Owns the Canariaco Project in Northern Peru

14 dec 2025, 22:01 UTC

Acquisities, Fusies, Overnames

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

14 dec 2025, 22:00 UTC

Acquisities, Fusies, Overnames

Fortescue: Agreement Implies Total Equity Value of C$139 Million

14 dec 2025, 22:00 UTC

Acquisities, Fusies, Overnames

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

14 dec 2025, 21:59 UTC

Acquisities, Fusies, Overnames

Fortescue to Acquire Remaining 64% of Alta Copper

14 dec 2025, 17:00 UTC

Winsten

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

14 dec 2025, 08:30 UTC

Acquisities, Fusies, Overnames

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

13 dec 2025, 16:48 UTC

Acquisities, Fusies, Overnames

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dec 2025, 08:00 UTC

Acquisities, Fusies, Overnames

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dec 2025, 07:00 UTC

Acquisities, Fusies, Overnames

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13 dec 2025, 00:24 UTC

Acquisities, Fusies, Overnames

Want a Piece Of SpaceX? -- Barrons.com

12 dec 2025, 23:49 UTC

Acquisities, Fusies, Overnames

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12 dec 2025, 22:52 UTC

Marktinformatie

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12 dec 2025, 22:32 UTC

Winsten

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 dec 2025, 20:45 UTC

Winsten

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12 dec 2025, 20:41 UTC

Marktinformatie

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12 dec 2025, 20:20 UTC

Marktinformatie

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12 dec 2025, 19:23 UTC

Winsten

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12 dec 2025, 18:35 UTC

Acquisities, Fusies, Overnames

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12 dec 2025, 18:33 UTC

Acquisities, Fusies, Overnames

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12 dec 2025, 18:31 UTC

Marktinformatie

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12 dec 2025, 17:49 UTC

Winsten

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12 dec 2025, 17:34 UTC

Acquisities, Fusies, Overnames

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Peer Vergelijking

Prijswijziging

Xenon Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

24.74% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 54.96 USD 24.74%

Hoogste 65 USD

Laagste 44 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor Xenon Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

Buy

Hold

Sell

Gebaseerd op 15 analisten die aandelenratings hebben gegeven aan Xenon Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

34.81 / 38.24Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

158 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.